MSH3 and Lynch syndrome: There has been no description of Lynch syndrome patients with a germline hMSH3 mutation to date to test the effect of adjuvant 5-FU treatment on outcome for this group, and perhaps their outcome would mirror patients with EMAST CRCs treated with 5-FU due to the remaining and functional hMutSα complex.